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A leucine-rich diet modulates the mTOR
cell signalling pathway in the
gastrocnemius muscle under different
Walker-256 tumour growth conditions
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Abstract
Background: The exact signalling mechanism of the mTOR complex remains a subject of constant debate, even
with some evidence that amino acids participate in the same pathway as used for insulin signalling during protein
synthesis. Therefore, this work conducted further study of the actions of amino acids, especially leucine, in vivo, in
an experimental model of cachexia. We analysed the effects of a leucine-rich diet on the signalling pathway of
protein synthesis in muscle during a tumour growth time-course.
Methods: Wistar rats were distributed into groups based on Walker-256 tumour implant and subjected to a
leucine-rich diet and euthanised at three different time points following tumour development (the 7th, 14th and
21st day). We assessed the mTOR pathway key-proteins in gastrocnemius muscle, such as RAG-A-GTPase, ERK/
MAP4K3, PKB/Akt, mTOR, p70S6K1, Jnk, IRS-1, STAT3, and STAT6 comparing among the experimental groups. Serum
WF (proteolysis-induced factor like from Walker-256 tumour) and muscle protein synthesis and degradation were
assessed.
Results: The tumour-bearing group had increased serum WF content, and the skeletal-muscle showed a reduction
in IRS-1 and RAG activation, increased PKB/Akt and Erk/MAP4K3 on the 21st day, and maintenance of p70S6K1,
associated with increases in muscle STAT-3 and STAT-6 levels in these tumour-bearing rats.
Conclusion: Meanwhile, the leucine-rich diet modulated key steps of the mTOR pathway by triggering the
increased activation of RAG and mTOR and maintaining JNK, STAT-3 and STAT-6 levels in muscle, leading to an
increased muscle protein synthesis, reducing the degradation during tumour evolution in a host, minimising the
cancer-induced damages in the cachectic state.
Keywords: Cancer cachexia, Leucine, mTOR cell signalling pathway, Eukaryotic Initialisation factors; Walker-256
tumour
Background
Branched-chain amino acids, especially leucine, play a
prominent role in the regulation of protein metabolism.
Both in vivo and in vitro studies corroborate the fact
that a diet supplemented with leucine stimulates protein
synthesis, particularly in skeletal muscle [1–4], and may
even reverse protein catabolism [5–7].
Cellular signalling in the setting of protein synthesis
involves the regulation of protein turnover in skeletal
muscle, a complex process that generally involves an
interaction between gene transcription and protein
translation and degradation. The stimulus and signal of
this process each come from outside the cell; the pri-
mary stimulating agents are anabolic hormones, such as
insulin, growth factors, glucose and nutrients, such as
amino acids, especially leucine [8–10].
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The mammalian protein kinase target of rapamycin,
mTOR, plays a central role in the development of skel-
etal muscle stimulation through growth by nutrition.
mTOR acts as a sort of strategic centre from which
various cellular processes are regulated [11, 12]. This
protein kinase is composed of the following two inde-
pendently adjustable complexes: mTOR Complex 1
(mTORC1) and mTOR Complex 2 (mTORC2), where
only mTORC1 is involved in cell signalling stimulated
by nutrition, as focused here mainly in muscle cells, es-
pecially because further studies about this pathway in
the cachectic host are necessary.
Leucine is the primary amino acid that activates pro-
tein synthesis in skeletal muscle [8, 9]. Some evidence
suggests that amino acids use the same pathway as that
used for insulin signalling, although the exact mechan-
ism by which signalling in the mTOR complex occurs
remains a subject of constant debate [13]. Considerable
evidence regarding the mechanism by which amino acids
act on mTOR pathway has been acquired from in vitro
studies using cell culture techniques. This information
indicates the need for further studies on the action of
amino acids in vivo, the primary purpose of our re-
search. Therefore, the primary purposes of our research
include investigating the time-course of tumour growth
under a leucine-rich diet and the effects of this diet on
the activation of upstream and down-stream proteins in-




The semi-purified isocaloric diets were a normal-protein
diet (C), containing 18% protein [14], and leucine (L), con-
taining 18% protein plus 3% L-leucine. Both diets con-
tained approximately 70% carbohydrate (sucrose, dextrin
and starch), 7% fat (soybean oil) and 5% fibre (purified
micro-cellulose). Vitamins and mineral mix, as well as
cystine and choline, supplemented the diets. The control
diet contained 1.6% L-leucine, and the leucine-rich diet
contained 4.6% L-leucine, according to previous experi-
mental studies [15].
Animal
Females Wistar rats (n = 72 animals; 90-days-old, weighing
180–200 g) were obtained from the Centre/UNICAMP ani-
mal facilities (CEMIB/State University of Campinas, Brazil),
and received food and water ad libitum under light-dark cy-
cles (12/12 h each) and constant temperature (22 + 2 °C)
and humidity (50–60%). The animals were distributed into
12 groups based on whether they were implanted with
Walker-256 tumour cells (1 × 106 viable cells, counted by
trypan blue exclusion), their periods of tumour develop-
ment analysis (7, 14 and 21 days after implantation), and
whether they received leucine-rich diet supplementation.
Each group contained a minimum of six animals as follows:
1. Control rats (7C; 14C and 21C) subjected to a normo-
proteic diet and euthanised on the 7th, 14th and 21st days
of the experiment; 2. Leucine rats (7 L, 14 L and 21 L) sub-
jected to leucine-rich diet and euthanised on the 7th, 14th
and 21st days of the experiment; 3. Tumour-bearing rats (7
W, 14W and 21W) subjected to a normoproteic diet, im-
planted with Walker 256 carcinosarcoma cells and eutha-
nised on the 7th, 14th and 21st days following tumour
development; 4. Leucine tumour-bearing rats (7WL, 14WL
and 21WL) subjected to leucine-rich diet, implanted with
Walker 256 carcinosarcoma cells and euthanised on the
7th, 14th and 21st days after tumour development.
The rats remained in collective cages throughout the
experimental period, and each group of animals was
euthanised by decapitation after 7, 14 or 21 days of
tumour inoculation in order to evaluate and establish
trends regarding changes in muscle profiles of cell sig-
nalling processes and the effects of these changes on
protein synthesis. The gastrocnemius muscle was dis-
sected; portions were weighed, quickly frozen in liquid
nitrogen and subsequently stored in a bio-freezer for fur-
ther biochemical and molecular analyses. The general
UKCCCR [16] guidelines for animal welfare were
followed, and the Institutional Committee for Ethics in
Animal Research approved the study protocol (CEEA/
IB/UNICAMP, protocol number #2418–1).
Multiplex analysis
The serum insulin was performed using an immuno-
assay kit (multiplex kit, Millipore, USA) according to the
manufacturer’s instructions and expressed as pM, using
a standard provided by the manufacturer with a range of
1 to 500 pM, and fluorescent flow cytometry with Lumi-
nex equipment (Millipore, USA).
The gastrocnemius muscle samples were homogenised in a
buffer sample (Milliplex MAP Cell Signalling Buffer –
Millipore, USA) according to the manufacturer’s instructions,
and analyses of the phosphorylated signalling proteins IRS-1,
Stat-3, Stat-6, Jnk, ERK/MAPK, Akt-PKB, p70S6K and mTOR
were completed using multiplex kits (Multiplex MAP Cells
Signalling Millipore, USA), according to the manufacturer’s in-
structions. The fluorescence of coupling beads with capture
antibodies specific for each protein of interest was measured
using the Luminex®200™ system (Luminex Corporation, TX,
USA). The analyses were carried out using xPonent® 3.1 Soft-
ware (Luminex Corporation, TX, USA) and the Luminex®200™
system. The protein phosphorylation are as follows:
p-IRS-1panTyr, p-Akt/PKBThr308, p-ERK/MAPK Thr185/Tyr187,
p-mTORSer2448, p-70S6KThr412, p-STAT3Ser727, p-STAT6Tyr641,
p-Jnk Thr/Tyr185, as provided by the manufacturer, and the
Millipore cell signalling kits tested for each antibody, using the
IP Western assay; the HeLa cell lysate was used as a positive
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control (provided by the Milliplex map kit detection by
Millipore).
Western blot
Serum samples were also resolved to analyse the
proteolysis-induced factor-like Walker Factor (WF) as
previously described by Yano and colleagues [17]. The
primary anti-WF antibody was produced at the Nutri-
tional Medicine Lab, School of Life and Health Sciences,
Aston University, Birmingham, UK, and gentle donated
by Dr. Michael J. Tisdale for use in our experiments.
The gastrocnemius muscles were homogenised with
homogenisation buffer (Tris Base 100mM, Na4P2O7 10
mM, FNa 100mM, Na3VO4 1mM, EDTA 10mM, PMSF
2mM, Aprotinin 0,1mg/mL, Triton X-100 1%, pH 7.4),
centrifuged, and divided into aliquots for a total protein
analysis [18]. We also verified the muscle expression of
RAS-related GTPase (RAG-A) (Affinity, USA, and diluted
1:1500). Either 2.5 μg of muscle homogenate protein or
serum total protein were resolved in the SDS-acrylamide
gel (12%) and transferred to 0.45 μm nitrocellulose mem-
brane. The protein expression of RAG-A in muscle and
WF in serum was assessed using secondary anti-rabbit
antibodies. Each protein expression level was corrected
against a GAPDH control load. The reaction was deter-
mined via chemiluminescence using an ECL reagent
(Amersham). Densitometry analysis of the protein bands
was performed using Image Capture (Amersham) and
analysed using Gel-Pro II software.
Protein synthesis and protein degradation assays
The protein synthesis was assayed in right gastrocnemius
muscles, as described by Ventrucci et al. [19]. The muscles
were weighed and placed in Krebs-Henseleit bicarbonate
(KHB) buffer (110mM NaCl; 25mM NaHCO3; 3.4mM
KCl; 1mM CaCl2; 1mM MgSO4 and 1mM KH2PO4, pH
7.4) supplemented with 5.5mM glucose and 0.01% (w/v) al-
bumin. The muscles were pre-incubated for 30min at 37 °
C with continuous gassing (95% O2–5% CO2). After this,
new KHB buffer supplemented with 5 μCi/ml of L-(3H)
phenylalanine (Amersham Life Science, NY, USA) was
added, and the incubation continued for further 2 h. At the
end of this period, the muscles were homogenised in
trichloroacetic acid (TCA 10%, 1:3w/v), centrifuged at
10.000×g and measured the total protein [18] and quantity
the radioactivity based on liquid scintillation of β emissions.
The rate of protein synthesis was calculated by the amount
of radioactive phenylalanine incorporated in the 2-h period
and was expressed as nmols (3H)-Phe per mg of muscle
protein [20].
Protein degradation was assessed using the left gastro-
cnemius muscles after rapidly excised, were placed in
RPMI 1640 medium and pre-incubated for 30 min under
the same conditions of temperature and gas as described
above. After the initial incubation, the solutions were re-
placed by KHB supplemented with cycloheximide
(130 μg.mL− 1) followed further 2 h incubation. The rate
of muscle protein degradation was determined as nmol of
tyrosine released per mg of muscle protein/ hour, based on a
fluorimetric assay described by Waalkes & Udenfriend [21].
The leucine and KIC incorporations into gastrocne-
mius muscle protein were assessed in other new muscles
samples from new similar experiments where the groups
were euthanised on 21st day of tumour evolution. Leu-
cine incorporation was assayed in right gastrocnemius
muscles, after weighing and placing the muscles in KHB
buffer supplemented with 1.26 mmol/L leucine. The KIC
incorporation into muscle protein was assayed in left
gastrocnemius muscles which were weight and placed in
KHB buffer supplemented with 0.26 mmol/L leucine and
1.0 mmol/L KIC. The right and left muscles were
pre-incubated, separately, for 30 min at 37 °C with con-
tinuous gassing (95%O2− 5%CO2). After this interval,
new KHB buffer supplemented with (3H)-leucine
(10 μCi.L− 1) or (14C) KIC (50 μCi.L− 1) (Amersham Life
Science, NY, USA) were added as a tracer, and the incu-
bation continued for further 2 h. At the end of this
period, the muscles were processed as the same proce-
dures described above, homogenising in trichloroacetic
acid, and assessed to measure the total protein [18] and
quantity the radioactivity based on liquid scintillation of
β emissions. The rates were calculated by the amount of
radioactive of leucine and KIC incorporated in 2-h
period and were expressed as nmols (3H)-Leu and
(14C)-KIC per mg of muscle protein [20].
Statistical analyses
The results were expressed as the mean ± standard devi-
ation. Two-way ANOVA followed by Fisher’s LSD mul-
tiple comparison test was used to compare the
experimental groups with the control group. A value of
P < 0.05 was considered significant [22].
Results
Our results showed the consequences of tumour evolution
in muscle protein signalling during a time-course of
Walker-256 tumour growth, and as present here, we
showed that leucine participated in signalling pathways in
parallel to insulin stimulation, modulating the Akt-PKB
pathway, and also mTOR via RAG GTPases.
Leucine-rich diet minimised the changes in insulin and
proteolysis-induced factor like – Walker factor – serum
content
We observed an increased content of Walker factor in
tumour-bearing rats at the 21st day (pre-agonic state) (Fig. 1),
and despite having a tumour, the leucine tumour-bearing
group (WL) showed a 14% lower content compared to W
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group (Fig. 1). The serum insulin decreased in the
tumour-bearing group (W), starting on the 14th day, and
became more prominent following the 21st day of the ex-
periment (Fig. 1 and Table 1). On the other hand, the leucine
tumour-bearing group (WL) maintained the serum insulin
levels compared with the control group, being different from
the W group (Fig. 1 and Table 1).
Leucine-rich diet increased the phosphorylation of RAG-A
and increased the pmTOR/pp70S6K1 ratio in muscle
In order to investigate the effects of tumour develop-
ment on muscle protein signalling, we analysed several
key proteins of mTOR pathway obtained from rats at 7,
14 and 21 days following tumour development, analysing
the proteogenesis cell signalling via. We verified that the
tumour development, as a time-course analysis, the
phospho IRS1/total-IRS1 ratio was decreased in W
group at 7th and 14th day after tumour implant in com-
parison to control group. In the opposite way, the phos-
pho AKT-PKB and phosphor ERK-MAPK increased in
muscle of tumour-bearing group (W) at the 21st day,
compared to the control group (Fig. 2; Table 1).
Although the phospho-mTOR and phosphor-p70S6K1
had a similar expression in W group compared to C group
along the experiment, but decreased phosphor-mTOR/
pp7-S6K1 ratio at the 21st day (Fig. 3, Table 1).
On the other hand, analysing the tumour-bearing ani-
mals subjected to leucine-rich diet, the Fig. 2 showed that
the WL group exhibited similar of IRS-1 activity levels as
those of the C group, which were slightly higher than
those of the W group on the 21st day of the experiment
(WL showed 1.9-times higher than W; P = 0.0628). There
are some evidence that leucine uses parallel stimulation
via mTOR and does not directly participate in the modu-
lation of Akt-PKB or activation of Erk/MAPK, therefore,
we verified similar values of muscle phospho AKT-PKB
and phosphor ERK-MAPK in WL group when compared
to control and leucine groups (Fig. 2 and Table 1). The
analysis of the concentration of phospho-mTOR in the
gastrocnemius muscle revealed a significant increase in
this concentration in the WL group especially at the 21st
day of the experiment compared with the other groups
(statistical significance noted on only the 21st day; Fig. 3;
Table 1). The WL group had similar values of phospho
p70S6K1, but the muscle phospho-mTOR/pp70S6K1 ratio
increased on the 21st day in this group WL compared to
W group (WL > 1.7-times; P = 0.0217). This difference was
more evident on the 21st day of the experiment, as the
groups that received leucine supplementation demon-
strated activation at this point of the pathway, which could
be evidenced by enhanced values of RAG-A expression es-
pecially in both groups subjected to leucine-rich diet. Des-
pite having a tumour, the WL group had an increase in
RAG-A 1.9-times when compared to W group (P = 0.004),
which likely indicated that the stimulus that acted on the
mTOR complex mostly resulted from the activation of
RAG-A GTPases (Fig. 3 and Table 1).
Leucine-rich diet modulated the downstream component
of mTOR pathway
In order to answer the question regarding the modulatory
effect of leucine supplementation, we analysed the STAT3
protein, a downstream component of mTOR complex 1
(mTORC1); Fig. 4 shows the profile of phospho-STAT3
Fig. 1 A profile of serum insulin (pM), a proteolysis-induced factor (Walker factor, WF, % compared to the control group). The animals were
euthanised at different times during tumour development to assess the profile of serum insulin including the 7th, 14th, and 21st days of the
experiment. The Walker Factor was assessed at 21st day of the experiment. Legend: C, control group; W, Walker tumour-bearing group; L, rats fed
a leucine-rich diet; WL, tumour-bearing rats fed a leucine-rich diet. Graphics represent mean ± standard deviation, and statistical significance is
presented in Table 1 after two-way Anova analysis, followed by the Fisher’s LSD multiple comparison test; P < 0.05
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among the groups, and only on day 21 showed difference
between W and C groups (W>C; P = 0.0174) and also
against the WL (W>WL 1.5-times; P = 0.0382) (Fig. 4;
Table 1). Adding to this analysis, the levels of
phospho-STAT6 were not significantly different during
the first two periods of the analysis (7 and 14 days) among
the groups, except comparing W group with C at the 14th
day (W>C; P= 0.013) (Fig. 4). On day 21, phospho-STAT6
showed differences in tumour-bearing groups when com-
pared to their respective groups without a tumour (phos-
pho-STAT6 was higher in W vs C; P= 0.0287, and was
increased in WL compared to L group; P= 0.0087) (Fig. 2
and Table 1). The stress-activated c-Jun amino-terminal
kinase (JNK), which plays a pivotal role in several
metabolic conditions, increased only in the skeletal
muscle of the W group compared with other groups
on the 7th day and the 21st day experiment com-
pared with the C and WL groups on the same days
of sacrifice (day 7 and day 21) (Fig. 4, Table 1).
Protein synthesis is increased in tumour-bearing group
subjected to leucine-rich diet
In order to investigate the positive effects of leucine-rich
diet, we accessed the protein synthesis and degradation
Table 1 A statistical analysis of serum content and the muscle key proteins of a protein synthesis pathway
7th day 14th day 21st day
Serum Insulin profile n.s. *W < C *W < C
*L > C
*W <WL
Serum Walker Factor n.d. n.d. *W > C
*W > L
*W >WL; P = 0.0517
Phospho IRS-1/total IRS-1 ratio *W < C *W < C; P = 0.056 n.s.
Phospho AKT-PKB n.s. *WL < L *W > C
*W > L
*WL <W
Phospho ERK-MAPK n.s. n.s. *W > C
*W > L
Phospho mTOR n.s. n.s. *WL > C
*WL > L
*WL >W
Phospho p70S6K n.s. n.s. n.s.
pmTOR/p70S6K-1 ratio *L > C
*WL < C
n.s. *W < C
*WL > C,L
*WL >W










Phospho JNK *W >WL n.s. n.s.
Phospho STAT3 n.s. n.s. *W > C
Phospho STAT6 n.s. *W > C *W > C
*W > L
Phenylalanine Incorporation n.d. n.d. *C >W
*L >WL
*WL >W
Leucine Incorporation n.d. n.d. *W < C; p = 0,058
KIC Incorporation n.d. n.d. *C >W
*WL >W
Tyrosine release n.d. n.d. *W > C
*WL > L
*W >WL
Total protein net n.d. n.d. *C >W
*L >WL
*WL >W
Legend: C, control group; W, Walker tumour-bearing group; L, rats fed a leucine-rich diet; WL, tumour-bearing rats fed a leucine-rich diet. Two Way ANOVA
analysis followed by the Fisher’s LSD multiple-comparison test (P < 0.05 values). * The mean difference of 0.05 is statistically significant. n.s. = non-significant. n.d.
= non-determined. For details, see the Materials and Methods and Results sections
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in the muscle of all groups. The phenylalanine in-
corporation into gastrocnemius muscle protein is
shown in Fig. 5a. Tumour growth reduced phenyl-
alanine incorporation in both tumour-bearing groups,
W and WL (Fig. 5a, Table 1), compared to C and L
groups, but the leucine tumour-bearing group (WL)
showed a 1.87-fold higher incorporation of phenyl-
alanine (3.88 ± 1.79 nmol (3H)-Phe /mg/h) than W
group (W = 2.07 ± 0.06 nmol (3H)-Phe /mg/h) (Fig. 5a,
Table 1).
With the same point of view, tumour growth reduced
leucine incorporation into muscle only in W group. How-
ever, the leucine incorporation in the tumour-bearing group
fed the leucine-rich diet (WL) was not significantly different
but showed an increased value (WL = 18.77 ± 2.57 nmol
[3H]-Leu/mg/h) when compared to W group (W= 14.00 ±
1.31 nmol [3H]-Leu/mg/h) (Fig. 5d, Table 1).
KIC incorporation indicates protein synthesis, stimulated
by indirect effect of leucine, which could be affected by
tumour growth, as we noted here where the W group had a
decrease in muscle KIC incorporation (Fig. 5e, Table 1), but
was 5.4-times higher in WL than in W group (W=2.50 ±
0.58 versus WL= 13.58 ± 1.39 nmol [14C]-KIC /mg/h).
Protein degradation is decreased in tumour-bearing
group with leucine-rich diet
In order to analyse the tumour wasting effect, we analysed
the muscle protein degradation by tyrosine released which
Fig. 2 Key-proteins related to the mTOR pathway: phosphorylated Akt-PKB, Erk/MAPK, and IRS-1 in the gastrocnemius muscle under the influence of
Walker-tumour development and nutritional supplementation with leucine. The minimum number of animals per group was 6. The animals were
euthanised at different times during tumour development, including the 7th, 14th, and 21st days of the experiment. Legend: C, control group; W,
Walker tumour-bearing group; L, rats fed a leucine-rich diet; WL, tumour-bearing rats fed a leucine-rich diet. Graphics represent mean ± standard
deviation. Statistical significance is presented in Table 1 after two-way Anova analysis, followed by the Fisher’s LSD multiple comparison test; P < 0.05
Fig. 3 mTOR, p70S6K-1, mTOR/p70S6K ratio and RAG-A (arbitrary units). The animals were euthanised at different times during tumour development,
including the 7th, 14th, and 21st days of the experiment. Legend: C, control group; W, Walker tumour-bearing group; L, rats fed a leucine-rich diet; WL,
tumour-bearing rats fed a leucine-rich diet. Graphics represent mean ± standard deviation. Statistical significance is presented in Table 1 after two-way
Anova analysis, followed by the Fisher’s LSD multiple comparison test; P < 0.05
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was increased in both tumour-bearing groups, W and
WL, compared to C and L groups (Fig. 5b). These data
reflected directly on total protein net (muscle’s phenyl-
alanine incorporation and tyrosine release ratio) (Fig. 5c),
which was notably reduced (~ 53%) in W group compared
to the other WL groups.
Discussion
The mTOR complex integrates various signalling path-
ways that are modulated by different stimuli, including
insulin, hypoxia, energy stress and nutrients [23]; the last
group stands out, as amino acids may serve as stimulants,
particularly leucine. Recent studies have shown that leu-
cine participates in signalling pathways in parallel to those
used by other stimuli [11, 24]. Therefore, although stimu-
lation by insulin modulates the Akt-PKB pathway, leucine
modulates mTOR via RAG GTPases [25, 26].
The present work contributed to deepening further
the results obtained in previous studies [27]. Therefore,
the present work analysed components of the mTOR
Fig. 4 A profile of phosphorylated JNK, STAT3 and STAT6 in the gastrocnemius muscle under the influence of Walker-tumour development and
nutritional supplementation with leucine. The minimum number of animals per group was 6. The animals were euthanised at different times
during tumour development, including 7th, 14th, and 21st day of the experiment. Legend: C, control group; W, Walker tumour-bearing group; L,
rats fed a leucine-rich diet; WL, tumour-bearing rats fed a leucine-rich diet. Graphics represent mean ± standard deviation. Statistical significance is
presented in Table 1 after two-way Anova analysis, followed by the Fisher’s LSD multiple comparison test; P < 0.05
a b c
d e
Fig. 5 Effects of a leucine-rich diet in gastrocnemius skeletal muscle from tumour-bearing rats. a Phenylalanine incorporation, b Tyrosine release, c
Total muscle protein net (represented by phenylalanine/tyrosine ratio), d Leucine incorporation, e KIC incorporation into muscle protein in different
groups. For details, see Methods. Abbreviations: C, control; L, leucine-rich diet group; W, tumour-bearing rats; WL, tumour-bearing rats fed a leucine-
rich diet. Graphics represent mean ± standard deviation. Statistical significance is presented in Table 1 after two-way Anova analysis, followed by the
Fisher’s LSD multiple comparison test; P < 0.05
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cell signalling pathway under the influence of leucine, in
the setting of cachexia; as mentioned above, this is the
first time that the effects of tumour development on
muscle protein synthesis were analysed during the
course of an experiment. Furthermore, the analysis of
these proteins at different stages of tumour development
provided us with more detailed insights into the time
course of activation or modulation as a result of nutri-
tional supplementation with leucine, which may be im-
portant in the management of co-adjuvant therapy in
patients with cancer.
Briefly, the Walker-256 tumour as an experimental
model of cachexia shows that its development increases
the muscle protein degradation by increasing the
proteolysis-induction factor-like – Walker-Factor - (WF)
levels, but also decreases the muscle protein synthesis by
reducing the insulin level, which was associated with
lower activation of IRS-1 in W group, especially after
the 14th and 21st day after implant. In parallel, we veri-
fied increases in the levels of phosphorylated Akt-PKB
and ERK/MAPK only at 21 days of tumour growth. Al-
though, these high levels of Akt did not lead to activa-
tion of mTOR via in muscle of these tumour-bearing
hosts, which clearly showed that the mTOR pathway
was compromised likely starting by the 14th day of
tumour development. On the other hand, one of the
downstream components of mTORC1, phospho-STAT3
had some variable profile with an expressive rise in the
muscle of these tumour-bearing groups on day 21. In-
deed, STAT3 mediates the expression of a variety of
genes in response to cellular stimuli and therefore plays
a key role in many cellular processes, including cell
apoptosis and inflammatory processes [27, 28]. STAT3
promotes oncogenesis by being constitutively active in
various pathways characterised by the activity of cyto-
kines and growth factors, including interleukins IL-6, as
previously noted in our study [29]. Therefore, we
hypothesised that the presence of tumour cells impaired
the function of the mTOR pathway, which paralleled the
effects attributed to increased phosphor-STAT3 levels in
muscle cells. Additionally, the levels of phospho-STAT6
showed a rising level, which was evidenced on the 21st
day of tumour development (W group). This protein
plays a central role in IL-4-mediated biological responses
during the inflammatory process [30]. It induces the ex-
pression of BCL2L1/BCL-X, which is responsible for the
anti-apoptotic activity of IL-4 [31]. Then, we likely sug-
gested that on 21st day, the tumour-bearing group (21
W) was subjected to more intense effects of the inflam-
matory process, higher interleukin IL-4 are associated
with increased levels of IL-6, TNF and INF in the W
group [29]. In addition, the stress-activated c-Jun
amino-terminal kinase (JNK), which plays a pivotal role
in several metabolic conditions, increased on 21st day in
the skeletal muscle of the W group. This protein partici-
pates in the cell-signalling pathway associated with stress
and inflammatory processes [32]. Tumour-bearing hosts,
particularly those of the animals in the W group, are in
a process characterised by inflammation and stress in
the setting of cachexia [29, 33, 34]. All these points
closely connected with the inflammatory process associ-
ated with the higher Walker-Factor levels in these
tumour-bearing rats inducing a low activity of mTOR
pathway associated with an increase on inflammatory
pathways (Fig. 6).
In order to investigate some of the benefits of
leucine-rich diet over the damage effects of tumour de-
velopment on muscle protein, here we analysed the pro-
file of these same key proteins of mTOR signalling
pathway, including phosphorylated proteins, from
up-stream and down-stream steps, which provided some
interesting point how the leucine-rich diet could modu-
late the tumour-induced damages in this experimental
model of cachexia.
In fact, the leucine-rich diet clearly demonstrated that
could ensure maintenance of serum insulin levels
throughout the course of tumour development, improv-
ing the muscle protein synthesis. Indeed, as presented
here, Petruzzelli et al. [35] observed a reduction in
serum insulin levels, particularly reduced insulin secre-
tion, after glucose stimulation, in islet cells isolated from
Walker 256 tumour-bearing rats. Insulin is an important
hormone and plays a prominent role in the physiologic
changes that occur in the setting of cachexia. For this
reason, we hypothesised that the WL group would most
likely benefit from nutritional supplementation, as
muscle protein was less wasted in W group (phenylalan-
ine incorporation and total protein net). It may be noted
that the administration of leucine notably modulated in-
sulin and also the proteolysis-induction factor-like (WF)
levels, which led to an improvement effect on the mTOR
cell signalling. The presence of leucine causing increases
in serum insulin content [11, 36, 37] and in part modu-
lating the WF levels, likely suggests the effect leading to
increased IRS-1 activation. On the other hand, we con-
firmed that the leucine-rich diet did not appear to have
affected signalling, by unchanged levels of phosphory-
lated Akt-PKB or ERK/MAPK, during the course of
tumour development. A recent study demonstrated that
leucine uses parallel stimulation via mTOR and does not
directly participate in the modulation of Akt-PKB [13].
Indeed, the analysis of the concentration of phosphor-
mTOR in the gastrocnemius muscle revealed an increase
in this concentration in the tumour-bearing group that
received a leucine-rich diet between the 14th and the
21st day of the experiment compared with the control
group and also with the non-supplemented tumour-
bearing group. Interestingly, leucine has been described
Cruz et al. BMC Cancer          (2019) 19:349 Page 8 of 12
by some researchers as an inhibitor of protein degrad-
ation and a stimulator of protein synthesis in cachectic
hosts [5, 38]. In this present study, we observed results
that are consistent with those noted by other re-
searchers, as we found that leucine most likely stimu-
lates protein synthesis through the mTOR signalling
pathway (as noted in the WL group), particularly over
longer time, such as 14 or 21 days of tumour develop-
ment. Indeed, the higher phospho-mTOR concentra-
tions are associated with higher serum insulin
concentration, as verified by other studies with
leucine-rich diet [29, 39, 40]. This fact was also con-
firmed by the amino-acid-signalling to mTORC1, which
is mediated by Rag GTPases [13]; additionally, we ob-
served that leucine led to a higher level with the differ-
ence more evident on the 21st day of the experiment in
tumour-bearing group WL (Fig. 3 and Table 1). The leu-
cine supplementation clearly demonstrated activation at
this point of the pathway, which indicates that the
stimulus that acted on the mTOR complex most likely
resulted from the activation of RAG GTPases (Fig. 3).
Amino acids signal the mechanistic and mammalian
TOR complex 1 (mTORC1) via the RAS-related
GTP-binding protein (RAG) family of small GTPases
([12, 13, 26]. The RAGs are assembled into heterodimers
containing RAG-A (as verified in this study), a process
stimulated by amino acids, particularly leucine [12]. In
spite of the evidence that mTOR was not permanently
increased in the L group, suggesting an adaptive process
that reached a steady state following 3 weeks of
leucine-rich dietary supplementation, the WL
tumour-bearing group showed that RAG-A facilitated
the stimulation of the mTOR pathway, confirming the
muscle response in the WL group that was noted in pre-
vious studies [7, 10, 39, 40]. Meanwhile, in order to an-
swer the question regarding the modulatory effect of
leucine supplementation, we analysed the downstream
component of mTOR complex 1 (mTORC1), the phos-
pho p70S6K protein demonstrated only limited variation
among the groups, which indicated that this portion of
the mTOR pathway was only minimally affected by
leucine supplementation. As mentioned above, we
hypothesised that the adaptive process involving leucine
supplementation might stimulate the mTOR pathway;
thus, the analysis of mTOR/p70S6K-1 ratio made it pos-
sible to determine that a stronger stimulus occurred in
the L group on the 7th day and continued as the experi-
ment progressed (14th and 21st day). Analysing the
tumour effect, the mTOR/p70S6K-1 stimulus that oc-
curred in WL group during the experiment differed
from that observed in the W group, especially after the
14th day, which was perfectly fitted to the raising of
Fig. 6 A scheme showing variations of key phosphorylated protein concentrations in the gastrocnemius muscle under the influence of tumour
development on different days of the experimental protocol (7th, 14th and 21st day), and under the influence of nutritional supplementation
with leucine
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phospho-mTOR and RAG-A expression, suggesting the
positive effect of leucine supplementation.
Considering the activation of downstream mTOR
pathway, the maintenance of STAT3 phosphorylation
occurred in WL group showed the leucine influence,
since the group without tumour cells or bearing a
tumour had constant levels of phospho-STAT3 over
the three study days compared with the C group. In-
deed, STAT3 mediates the expression of a variety of
genes in response to cellular stimuli, in this case be-
ing modulated by leucine effects. We suggest that the
STAT3 could be likely activated in various pathways
characterised by the activity of cytokines and growth
factors, including interleukins IL-6, as previously
noted in your study [29], but under leucine supple-
mentation, this downstream protein could be reduced
benefiting the skeletal muscle in these tumour-bearing
animals (Fig. 4). Constitutive STAT3 activation is as-
sociated with various human cancers and often sug-
gestive of a poor prognosis, mostly related to
inflammatory processes [27]. However, leucine supple-
mentation interfered with this process, as muscle
STAT3 activation was similar to that noted in the
control groups (C and L; Fig. 4). In this same view,
the raises of phospho-STAT6 and JNK in muscles of
tumour-bearing rats leads us to the thought that the
muscle catabolic process was directly related to the
increase of pro-inflammatory cytokines from day 14th
of tumour development, as previously shown by Cruz
and colleagues [29]; although the leucine-rich diet
also contributed to reducing this tumour-induced
damage over skeletal muscle decreasing these proteins
especially after day 14 of the experiment (Fig. 4). We
hypothesised that on 21st day, the tumour-bearing
group was subjected to more intense effects of the inflam-
matory process [29]. This change was smaller in the
tumour-bearing rats subjected to leucine supplementa-
tion. The stress-activated c-Jun amino-terminal kinase
(JNK) participates in the cell-signalling pathway associ-
ated with stress and inflammatory processes, which in
particularly those of the animals in the W group are in
inflammation and stress processes in the setting of
cachexia, particularly when the Walker-tumour cell
burden exceeds 10% of an animal’s body weight (in this
study, the tumour/body weight ratio reached more than
12%, [29]), as noted previously by several researchers
[34, 41, 42]. As noted in our previous studies, leucine
stimulates protein synthesis [10, 39, 40]; therefore,
based on the results obtained in this study, it is possible
that a component acting in parallel to the mTOR sig-
nalling pathway acts as a result of leucine stimulation,
leading to increase in muscle protein synthesis, mini-
mising the effects of the tumour cells as a result of
decreasing WF levels.
After analyse those time-course experiments we
choose the 21st day as a point of more pronounced ef-
fect of a tumour and leucine-rich diet on animals’ body.
Therefore, radioactive experiments were performed only
on the 21st day of tumour development.
Leucine stimulates muscle protein synthesis and
modules the activity of various proteins involved in the
control of mRNA translation [43]. Leucine can stimu-
late protein synthesis directly and/or via its metabolite,
as α-ketoisocaproic acid (KIC). These findings are
corroborated by the data on protein synthesis and
degradation contained in Fig. 5. It can be noted that
the presence of leucine stimulates protein synthesis
through increased incorporation of phenylalanine and
KIC (a ketoacid converted from Leucine). In contrast,
the group fed a control diet and tumour-bearing pre-
sents lower protein synthesis and higher degradation
rates. Since protein synthesis is reduced and protein
degradation is increased throughout the body during
cancer cachexia, the incorporation of amino acids, es-
pecially branched-chain amino acids, by muscle cells
could supply important nutrients and influence protein
synthesis. The lower incorporation of leucine into
gastrocnemius muscle proteins in tumour-bearing rats
indicated a decrease in protein synthesis that paralleled
an increase in protein wasting [40, 44, 45]. As shown
here, the leucine-rich diet reduced the protein catabol-
ism and increased the protein synthesis in WL rats
compared to W rats.
These finds clearly show the minimisation of tumour-in-
duced damage effects when these tumour-bearing rats were
subjected to leucine-rich diet. Leucine supplementa-
tion appeared to reduce the effects of stress in the
host body, as well as effects of the inflammatory pro-
cesses generated by the presence of the tumour cells
improving the host’s responses and maintaining lean
body mass (Fig. 6).
Conclusions
This work demonstrates for the first time a time-
course study with action of leucine anticipating and
enhancing the parameters analysed in the setting of
tumour growth; this involves the stimulation of pro-
tein synthesis, which results in reduced cachexia and
occurs primarily in the experiment that achieves the
best values on the 21st day following the start of the
experiment. These results are consistent with those
observed in previous studies performed by our re-
search group. It was also noted that leucine stimu-
lates various points of the mTOR pathway, including
different anabolic hormones via, such as insulin. Fur-
ther study is necessary in order to completely under-
stand the effects of leucine on protein synthesis and
protein degradation at the molecular level.
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Abbreviations
14 L: Leucine rats subjected to leucine-rich diet and euthanised on the 14th
day of the experiment; 14 W: Tumour-bearing rats subjected to a
normoproteic diet, implanted with Walker 256 carcinosarcoma cells and
euthanised on the 14th day following tumour development; 14C: Control
rats subjected to a normoproteic diet and euthanised on the 14th day of the
experiment; 14WL: Leucine tumour-bearing rats subjected to leucine-rich
diet, implanted with Walker 256 carcinosarcoma cells and euthanised on the
14th day after tumour development; 21 L: Leucine rats subjected to leucine-
rich diet and euthanised on the 21st day of the experiment; 21 W: Tumour-
bearing rats subjected to a normoproteic diet, implanted with Walker 256
carcinosarcoma cells and euthanised on the 21st day following tumour
development; 21C: Control rats subjected to a normoproteic diet and
euthanised on the 21st day of the experiment; 21WL: Leucine tumour-
bearing rats subjected to leucine-rich diet, implanted with Walker 256 carci-
nosarcoma cells and euthanised on the 21st day after tumour development;
7 L: Leucine rats subjected to leucine-rich diet and euthanised on the 7th
day of the experiment; 7 W: Tumour-bearing rats subjected to a
normoproteic diet, implanted with Walker 256 carcinosarcoma cells and
euthanised on the 7th day following tumour development; 7C: Control rats
subjected to a normoproteic diet and euthanised on the 7th day of the
experiment; 7WL: Leucine tumour-bearing rats subjected to leucine-rich diet,
implanted with Walker 256 carcinosarcoma cells and euthanised on the 7th
day after tumour development; ERK/MAP4K3: Mitogen-activated protein
kinase 3; IRS-1: Insulin receptor substrate 1; JNK: stress-activated c-Jun amino-
terminal kinase; mTOR: mechanistic target of rapamycin; p70S6K1: Ribosomal
protein S6 kinase beta-1; PKB/Akt: Protein kinase B; RAG-A-GTPase: Rag small
GTPases heterodimer A; STAT3: Signal transducer and activator of
transcription 3; STAT6: Signal transducer and activator of transcription 6;
Walker-256 tumour: Wistar rats carcinosarcoma; WF: proteolysis-induced
factor like from Walker-256 tumour
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